Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M

Fulcrum Therapeutics, Inc.

2025-FY EPS reported -$1.18

Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.
Fulcrum plans to initiate a potential registration-enabling trial in H2 2026 after FDA End-of-Phase meeting in Q2 2026.
Cash, cash equivalents, and marketable securities of $352.3M as of Dec 31, 2025; cash runway extended into 2029.
Net loss for FY2025 was $74.9M vs $9.7M in FY2024; R&D expenses decreased to $56.1M from $63.4M.
Discontinued bone marrow failure syndrome program; focus on pociredir and benign hematology pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.